Latest & greatest articles for pregabalin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregabalin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregabalin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregabalin

21. Systematic review and meta-analysis: Pregabalin is effective in reducing fibromyalgia pain

Systematic review and meta-analysis: Pregabalin is effective in reducing fibromyalgia pain Pregabalin is effective in reducing fibromyalgia pain | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pregabalin is effective in reducing fibromyalgia pain Article Text Therapeutics/Prevention Systematic review and meta-analysis Pregabalin is effective in reducing fibromyalgia pain Charles Argoff Statistics from Altmetric.com Commentary on: Derry

2017 Evidence-Based Medicine

22. Pregabalin for essential tremor. Full Text available with Trip Pro

Pregabalin for essential tremor. Essential tremor is one of the most common movement disorders. Treatment primarily consists of pharmacological agents. While primidone and propranolol are well-established treatments in clinical practice, they may be ineffective in 25% to 55% of patients and can produce serious adverse events in a large percentage of them. For these reasons, it is worth evaluating the treatment alternatives for essential tremor. Some specialists have suggested that pregabalin (...) could be a potentially useful agent, but there is uncertainty about its efficacy and safety.To assess the effects of pregabalin versus placebo or other treatment for essential tremor in adults.We performed a systematic search without language restrictions to identify all relevant trials up to December 2015. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, NICE, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry

2016 Cochrane

23. Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes Full Text available with Trip Pro

Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes To evaluate the comparative safety and adjunctive efficacy of pregabalin and gabapentin in reducing seizure frequency in patients with partial-onset seizures based on prestudy modeling showing superior efficacy for pregabalin.The design of this comparative efficacy and safety study of pregabalin and gabapentin as adjunctive treatment in adults with refractory partial-onset seizures was randomized (...) , flexible dose, double blind, and parallel group. The study included a 6-week baseline and a 21-week treatment phase. The primary endpoint was the percentage change from baseline in 28-day seizure rate to the treatment phase.A total of 484 patients were randomized to pregabalin (n = 242) or gabapentin (n = 242). Of these, 359 patients (187 pregabalin, 172 gabapentin) completed the treatment phase. The observed median and mean in percentage change from baseline was -58.65 and -47.7 (SD 48.3

2016 EvidenceUpdates Controlled trial quality: predicted high

24. Pregabalin for pain in fibromyalgia in adults. Full Text available with Trip Pro

Pregabalin for pain in fibromyalgia in adults. This review updates part of an earlier Cochrane review on 'Pregabalin for acute and chronic pain in adults' (Moore 2009), and considers only fibromyalgia pain.Antiepileptic drugs have been used in pain management since the 1960s. Pregabalin is an antiepileptic drug also used in management of chronic pain conditions, including fibromyalgia. Pain response with pregabalin is associated with major benefits for other symptoms, and improved quality (...) of life and function in people with chronic painful conditions.To assess the analgesic efficacy and adverse events of pregabalin for pain in fibromyalgia in adults, compared with placebo or any active comparator.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE for randomised controlled trials from inception to May 2009 for the original review and to 16 March 2016 for this update. We also searched the reference lists of retrieved studies and reviews

2016 Cochrane Controlled trial quality: predicted high

25. Prior Opioid Use Does Not Impact the Response to Pregabalin in Patients With Fibromyalgia (Abstract)

Prior Opioid Use Does Not Impact the Response to Pregabalin in Patients With Fibromyalgia Fibromyalgia (FM) is a chronic pain disorder for which pregabalin is an approved treatment in the United States. Although opioids are not a recommended treatment option, they continue to be used by many FM patients. The impact of patients' prior opioid use on their subsequent response to pregabalin has not been assessed.This was a pooled analysis of 4 clinical trials to assess the efficacy of pregabalin (...) in FM patients both with and without prior opioid use. Patients were divided into those using opioids prior to the trial and those who were not. The change in least squares mean pain score (assessed by 0 to 10 numeric rating scale) with pregabalin compared with placebo was assessed together with FM symptoms, anxiety, and depression.There were 2062 patients in the analysis set, including 371 patients with prior opioid use. Equal numbers of patients were treated with placebo, pregabalin 300 mg/d

2016 EvidenceUpdates Controlled trial quality: uncertain

26. Pregnancy outcome following maternal exposure to pregabalin may call for concern Full Text available with Trip Pro

Pregnancy outcome following maternal exposure to pregabalin may call for concern To investigate pregnancy outcomes following maternal use of pregabalin.This multicenter, observational prospective cohort study compared pregnancy outcomes in women exposed to pregabalin with those of matched controls (not exposed to any medications known to be teratogenic or to any antiepileptic drugs). Teratology Information Services systematically collected data between 2004 and 2013.Data were collected from 164 (...) exposed pregnancies and 656 controls. A significantly higher major birth defect rate in the pregabalin group was observed after exclusion of chromosomal aberration syndromes, and when cases with exposure during first trimester of pregnancy were analyzed separately (7/116 [6.0%] vs 12/580 [2.1%]; odds ratio 3.0, 95% confidence interval 1.2-7.9, p = 0.03). The rate of live births was lower in the pregabalin group (71.9% vs 85.2%, p < 0.001), primarily due to a higher rate of both elective (9.8% vs 5.0

2016 EvidenceUpdates

27. Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial (Abstract)

Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial Chronic refractory cough (CRC) is a difficult problem to treat. Speech pathology treatment (SPT) improves symptoms but resolution is incomplete. Centrally acting neuromodulators also improve cough symptoms, but not cough reflex sensitivity, and the effect is short-lived. We hypothesized that combined SPT and centrally acting neuromodulators would have a superior outcome than SPT alone (...) . Our goal was to determine whether combined pregabalin and SPT is more effective than SPT alone.Randomized placebo controlled trial. Forty patients with CRC were randomly assigned to receive either combined SPT and pregabalin 300 mg daily or combined SPT and placebo. Outcome measures were collected at baseline, end of treatment, and 4 weeks after the end of treatment. Primary outcome measures were cough frequency using the Leicester Cough Monitor, cough severity using a visual analog scale

2016 EvidenceUpdates Controlled trial quality: predicted high

28. Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy Using an NSAID for Other Pain Conditions: A Double-Blind Crossover Study (Abstract)

Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy Using an NSAID for Other Pain Conditions: A Double-Blind Crossover Study To evaluate pregabalin's efficacy and safety versus placebo to reduce pain in patients with diabetic peripheral neuropathy (DPN) using a concomitant nonsteroidal anti-inflammatory drug.In a randomized, double-masked, 14-week, 2-period, crossover study, patients with painful DPN using a nonsteroidal anti-inflammatory drug for non-DPN-related pain received (...) 150 to 300 mg/d pregabalin or placebo (period 1); 14-day washout; then, the opposite therapy (period 2). Endpoints included weekly change in DPN pain score, sleep interference, adverse events, and patient-reported outcomes.Patients with similar baseline characteristics were randomized (period 1) to 1 of the 2 following possible sequences: pregabalin→placebo (n=154) or placebo→pregabalin (n=147). Results of the primary efficacy measure, mean weekly DPN pain at endpoint, showed no significant

2016 EvidenceUpdates Controlled trial quality: predicted high

29. Pregabalin for decreasing pancreatic pain in chronic pancreatitis. Full Text available with Trip Pro

Pregabalin for decreasing pancreatic pain in chronic pancreatitis. Chronic abdominal pain is one of the major symptoms in people with chronic pancreatitis. The role of pregabalin in people with chronic pancreatic pain due to chronic pancreatitis is uncertain.To assess the benefits and harms of pregabalin in people with chronic abdominal pain due to chronic pancreatitis.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library 2015, issue 6, and MEDLINE (...) difference (MD) with 95% confidence intervals (CI) with RevMan 5, based on intention-to-treat analysis.Only one study, funded by Pfizer, met the inclusion criteria for the review. A total of 64 participants (with chronic pain due to chronic pancreatitis) were randomly assigned to receive escalating doses of pregabalin (150 mg per day to 600 mg per day; 34 participants) or matching placebo (30 participants). Participants received pregabalin or placebo for three weeks on an outpatient basis; the outcomes

2016 Cochrane

30. Efficacy and Safety of Pregabalin in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy and Pain on Walking (Abstract)

Efficacy and Safety of Pregabalin in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy and Pain on Walking This randomized, double-blind, placebo-controlled, multicenter, 2-period crossover study (two 6-week treatment periods separated by a 2-week washout period) evaluated the efficacy and safety of pregabalin (150 to 300 mg/d) for treatment of pain and pain on walking in patients with painful diabetic peripheral neuropathy (DPN) who experienced pain while walking.Co-primary (...) efficacy endpoints were: (1) mean pain score (last 7 daily pain diary scores, 0 to 10 numeric rating scale at end of each treatment period) and (2) DPN pain on walking (0 to 10 numeric rating scale immediately after walking 50 feet [15.2 m] on flat surface). Secondary endpoints included other pain parameters, patient-reported sleep, health-related quality of life, and safety measures.Two hundred three patients were treated (pregabalin, n=198; placebo, n=186), with no statistically significant treatment

2015 EvidenceUpdates Controlled trial quality: predicted high

31. Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial (Abstract)

Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial Monotherapy with first-line drugs for neuropathic pain often fails to provide sufficient pain relief or has unacceptable side effects because of the need for high doses. The aim of this trial was to test whether the combination of imipramine and pregabalin in moderate doses would relieve pain more effectively than monotherapy with either of the drugs. This was a randomized, double-blind, placebo (...) -controlled, crossover, multicenter trial consisting of four 5-week treatment periods in patients with painful polyneuropathy. Treatment arms were imipramine 75 mg/d vs pregabalin 300 mg/d vs combination therapy vs placebo. Patients with polyneuropathy and symptoms for more than 6 months, age 20 to 85 years, pain intensity ≥4 on a 0- to 10-point numeric rating scale (NRS) and pain at least 4 days a week were included in the trial. A total of 262 patients were screened for participation, 73 patients were

2015 EvidenceUpdates Controlled trial quality: predicted high

32. Pregabalin Mylan Pharma

Pregabalin Mylan Pharma 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 23 April 2015 EMA/CHMP/90102/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Pregabalin Mylan Pharma International non-proprietary name: pregabalin Procedure No. EMEA/H/C/003962/0000 Note Assessment report as adopted by the CHMP (...) with all information of a commercially confidential nature deleted. Assessment Report EMA/CHMP/90102/2015 Page 2/29 Administrative information Name of the medicinal product: Pregabalin Mylan Pharma Applicant: Generics UK Limited Station Close Potters Bar Hertfordshire EN6 1TL UNITED KINGDOM Active substance: pregabalin International Nonproprietary Name/Common Name: pregabalin Pharmaco-therapeutic group (ATC Code): Pregabalin (N03AX16) Therapeutic indications: Neuropathic pain Pregabalin Mylan Pharma

2015 European Medicines Agency - EPARs

33. Pregabalin Zentiva

Pregabalin Zentiva 26 May 2015 EMA/CHMP/408316/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Pregabalin Zentiva International non-proprietary name: PREGABALIN Procedure No. EMEA/H/C/003900/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 (...) . Pharmacovigilance 18 2.6. Risk management plan 18 2.7. PSUR submission 22 2.8. Product information 22 2.8.1. User consultation 22 3. Benefit-risk balance 22 4. Recommendation 23 Pregabalin Zentiva Assessment report EMA/CHMP/408316/2015 Page 2/24 List of abbreviations AE adverse event API Active Pharmaceutical Ingredient AR Assessment Report ASM Active Substance Manufacturer ASMF Active Substance Master File = Drug Master File AUC Area Under the plasma Concentration AUC0-inf Area Under the plasma Concentration

2015 European Medicines Agency - EPARs

34. Pregabalin Mylan

Pregabalin Mylan 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 23 April 2015 EMA/CHMP/90129/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Pregabalin Mylan International non-proprietary name: pregabalin Procedure No. EMEA/H/C/004078/0000 Note Assessment report as adopted by the CHMP with all (...) information of a commercially confidential nature deleted. Assessment report EMA/CHMP/90129/2015 Page 2/29 Administrative information Name of the medicinal product: Pregabalin Mylan Applicant: Generics (UK) Limited Station Close Potters Bar Hertfordshire EN6 1TL UNITED KINGDOM Active substance: pregabalin International Nonproprietary Name/Common Name: pregabalin Pharmaco-therapeutic group (ATC Code): Pregabalin (N03AX16) Therapeutic indications: Epilepsy Pregabalin Mylan is indicated as adjunctive therapy

2015 European Medicines Agency - EPARs

35. Pregabalin Accord

Pregabalin Accord 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 25 June 2015 EMA/CHMP/282380/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Pregabalin Accord International non-proprietary name: pregabalin Procedure No. EMEA/H/C/004024/0000 Note Assessment report as adopted by the CHMP with all (...) (EMA) for Pregabalin Accord, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004– ‘Generic of a Centrally authorised product’. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 22 May 2014. The application concerns a generic medicinal product as defined in Article 10(2)(b) of Directive 2001/83/EC and refers to a reference product for which a Marketing Authorisation is or has been granted in the Union on the basis of a complete dossier

2015 European Medicines Agency - EPARs

36. Pregabalin Sandoz GmbH

Pregabalin Sandoz GmbH 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 26 May 2015 EMA/CHMP/102870/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Pregabalin Sandoz GmbH International non-proprietary name: pregabalin Procedure No. EMEA/H/C/004070 Note Assessment report as adopted by the CHMP (...) with all information of a commercially confidential nature deleted. Pregabalin Sandoz GmbH Assessment report EMA/CHMP/102870/2015 Page 2/23 Table of contents 1. Background information on the procedure 4 1.1. Submission of the dossier 4 1.2. Manufacturers 5 1.3. Steps taken for the assessment of the product 6 2. Scientific discussion 6 2.1. Introduction 6 2.2. Quality aspects 7 2.2.1. Introduction 7 2.2.2. Active substance 7 2.2.3. Finished medicinal product 9 Adventitious agents 11 2.2.4. Discussion

2015 European Medicines Agency - EPARs

37. Pregabalin Sandoz

Pregabalin Sandoz 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 23 April 2015 EMA/CHMP/102862/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Pregabalin Sandoz International non-proprietary name: pregabalin Procedure No. EMEA/H/C/004010 Note Assessment report as adopted by the CHMP with all (...) information of a commercially confidential nature deleted. Pregabalin Sandoz Assessment report EMA/CHMP/102862/2015 Page 2/23 Table of contents 1. Background information on the procedure 4 1.1. Submission of the dossier 4 1.2. Manufacturers 5 1.3. Steps taken for the assessment of the product 6 2. Scientific discussion 6 2.1. Introduction 6 2.2. Quality aspects 7 2.2.1. Introduction 7 2.2.2. Active substance 7 2.2.3. Finished medicinal product 9 2.2.4. Discussion on chemical, and pharmaceutical aspects 11

2015 European Medicines Agency - EPARs

38. Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication Full Text available with Trip Pro

Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication To test the effects of pregabalin on the induction of neurogenic claudication.This study was a randomized, double-blind, active placebo-controlled, 2-period, crossover trial. Twenty-nine subjects were randomized to receive pregabalin followed by active placebo (i.e., diphenhydramine) or active placebo followed by pregabalin. Each treatment period lasted 10 days, including a 2-step titration. Periods (...) Brief Pain Inventory-Short Form, Oswestry Disability Index, and Swiss Spinal Stenosis Questionnaire.No significant difference was found between pregabalin and active placebo for the time to first moderate pain symptom (difference in median Tfirst = -1.08 [95% confidence interval -2.25 to 0.08], p = 0.61). In addition, none of the secondary outcome measures of pain or functional limitation were significantly improved by pregabalin compared with active placebo.Pregabalin was not more effective than

2015 EvidenceUpdates Controlled trial quality: predicted high

39. Gabapentin and pregabalin: major adverse effects

Gabapentin and pregabalin: major adverse effects Prescrire IN ENGLISH - Spotlight ''Gabapentin and pregabalin: major adverse effects'', 1 November 2014 {1} {1} {1} | | > > > Gabapentin and pregabalin: major adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Gabapentin and pregabalin: major adverse effects To reduce the consequences (...) of some severe adverse effects associated with gabapentin or pregabalin, it is advisable not to expose patients to them other than in situations where these drugs have proved to be highly effective. Gabapentin and pregabalin are used in certain epilepsies and for pain in neurological diseases. Pregabalin is also used to treat anxiety disorders. According to a review of French pharmacovigilance data published in 2013, between 1995 and 2009, 2415 adverse effects linked to gabapentin or pregabalin were

2014 Prescrire

40. Comparison of pregabalin with pramipexole for restless legs syndrome. Full Text available with Trip Pro

Comparison of pregabalin with pramipexole for restless legs syndrome. Dopaminergic medications relieve symptoms of the restless legs syndrome (RLS) but have the potential to cause iatrogenic worsening (augmentation) of RLS with long-term treatment. Pregabalin may be an effective alternative.In this 52-week, randomized, double-blind trial, we assessed efficacy and augmentation in patients with RLS who were treated with pregabalin as compared with placebo and pramipexole. Patients were randomly (...) assigned to receive 52 weeks of treatment with pregabalin at a dose of 300 mg per day or pramipexole at a dose of 0.25 mg or 0.5 mg per day or 12 weeks of placebo followed by 40 weeks of randomly assigned active treatment. The primary analyses involved a comparison of pregabalin and placebo over a period of 12 weeks with use of the International RLS (IRLS) Study Group Rating Scale (on which the score ranges from 0 to 40, with a higher score indicating more severe symptoms), the Clinical Global

2014 NEJM Controlled trial quality: predicted high